Some drugmakers are worried that the pace of drug approvals could slow after Janet Woodcock retires as director of the FDA's Center for Drug Evaluation and Research, according to this article. Woodcock has served in that role for two decades and is at least a year away from leaving it. FDA divestment rules and other obstacles can make it hard to find a successor, she said.

Full Story:

Related Summaries